← Back to Search

Immunotherapy

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1
Waitlist Available
Led By Mark Markowski, MD
Research Sponsored by Calibr, a division of Scripps Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new immunotherapy drug for prostate cancer. The goal is to find the maximum tolerated dose and to assess the safety and effectiveness of the drug.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Part 1a and 1b: Assess the safety and tolerability of CCW702, including incidence of dose limiting toxicities
Part 1a and 1b: Select recommended phase/part 2 dose
Part 2: to assess clinical efficacy at the RP2D

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Part 2: Dose ExpansionExperimental Treatment1 Intervention
CCW702 administered subcutaneously Q7D at RP2D.
Group II: Part 1b: Dose Escalation Q7DExperimental Treatment1 Intervention
CCW702 administered subcutaneously Q7D, dose escalating cohorts.
Group III: Part 1a: Dose Escalation QODExperimental Treatment1 Intervention
CCW702 administered subcutaneously QOD, dose escalating cohorts.

Find a Location

Who is running the clinical trial?

Calibr, a division of Scripps ResearchLead Sponsor
6 Previous Clinical Trials
317 Total Patients Enrolled
Mark Markowski, MDPrincipal InvestigatorJohns Hopkins University Hospital - Sidney Kimmel Comprehensive Cancer Center
1 Previous Clinical Trials
12 Total Patients Enrolled
~4 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top